Your session is about to expire
← Back to Search
BMS-986253 for Myelodysplastic Syndrome
Study Summary
This trial is testing a new drug to treat myelodysplastic syndromes, to see if it is safe and effective. Eligible participants must be adults over 18, and treatment will happen in 28-day cycles.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I do not have active or uncontrolled autoimmune diseases.My liver and kidney functions meet the trial's requirements.I do not have any unmanaged ongoing illnesses.I have low platelet counts that don't respond to transfusions or dangerously low white blood cell counts.I can take care of myself but might not be able to do active work.I have not had any other cancer in the last 2 years.I have MDS with specific blood counts and have had certain treatments.I have had a stem cell transplant from a donor.I have chronic hepatitis B or C.I have high-risk MDS and have had less than 2 treatments with DNMTi.I do not have any major health issues that could affect my treatment.My condition is officially diagnosed as MDS.I am 18 years old or older.I am HIV-positive.
- Group 1: escalating doses of treatment for LR-MDS
- Group 2: phase II dose of BMS-986253 for LR-MDS
- Group 3: escalating dose of treatment for HR-MDS
- Group 4: phase II dose of BMS-986253 for HR-MD
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Have decitabine and cedazuridine been previously tested in any other clinical studies?
"At present, there are 104 active trials researching the effects of decitabine and cedazuridine. Of these, 16 have advanced into phase 3 clinical studies. The majority of the experiments occur in Philadelphia, Pennsylvania; although additional sites across 1491 locations are also conducting research on this treatment."
How many participants are enrolled in this experiment?
"Affirmative. As per information on clinicaltrials.gov, this study is currently enrolling patients and was initially posted on December 1st 2022. The trial seeks to recruit 200 participants from a single site and its data has been recently updated as of November 25th 2022."
How have decitabine and cedazuridine been traditionally used to treat patients?
"For patients in the intermediate-2 IPSS risk category, decitabine and cedazuridine are often prescribed. This treatment can also prove beneficial for high IPSS risk individuals, those with refractory anemias, or struggling with anemia."
Is this research initiative open to new participants at present?
"According to clinicaltrials.gov, this medical investigation is presently enrolling participants and has been open for application since December 1st of 2022. It was last updated on November 25th of the same year."
Share this study with friends
Copy Link
Messenger